BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report issued on Saturday.

Several other equities analysts have also recently commented on RARE. Raymond James Financial restated a buy rating on shares of Ultragenyx Pharmaceutical in a report on Friday, December 15th. Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a hold rating to a sell rating in a report on Wednesday, January 10th. Credit Suisse Group started coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 17th. They set an outperform rating and a $67.00 price target on the stock. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a report on Monday, January 22nd. Finally, Stifel Nicolaus reiterated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company. Ultragenyx Pharmaceutical currently has an average rating of Buy and an average target price of $68.76.

How to Become a New Pot Stock Millionaire

Ultragenyx Pharmaceutical stock opened at $53.82 on Friday. Ultragenyx Pharmaceutical has a 12 month low of $41.67 and a 12 month high of $71.99. The firm has a market cap of $2,635.06, a PE ratio of -7.18 and a beta of 1.82.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) EPS for the quarter, missing the consensus estimate of ($2.00) by ($0.27). The firm had revenue of $2.41 million for the quarter, compared to analyst estimates of $0.75 million. During the same quarter in the prior year, the company posted ($1.75) EPS. sell-side analysts predict that Ultragenyx Pharmaceutical will post -6.03 earnings per share for the current year.

Large investors have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Ultragenyx Pharmaceutical by 1,246.9% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock valued at $152,000 after acquiring an additional 3,030 shares during the period. SG Americas Securities LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $156,000. Xact Kapitalforvaltning AB bought a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at about $205,000. B. Riley Financial Inc. bought a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at about $213,000. Finally, Aperio Group LLC bought a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at about $254,000. Hedge funds and other institutional investors own 87.19% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Ultragenyx Pharmaceutical (RARE) Upgraded at BidaskClub” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.watchlistnews.com/ultragenyx-pharmaceutical-rare-upgraded-at-bidaskclub/2031828.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.